Central nervous system (CNS) disorders (eg, multiple sclerosis, Alzheimer's disease, etc.)
represent a growing public health issue, primarily due to the increased life expectancy and …

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders
has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits …

Introduction: The blood–brain barrier (BBB) represents a stringent barrier for delivery of
neurotherapeutics in vivo. An attempt to overcome this barrier is represented by the direct …

Background Cranial nerve-related diseases such as brain tumors, Alzheimer's disease, and
epilepsy are serious diseases that continue to threaten human. Brain-related diseases are …

The treatment of neurodegenerative and psychiatric disorders remains a challenge in
medical research. Several strategies have been developed over the years, either to …

Nose-to-brain delivery represents a big challenge. In fact there is a large number of
neurological diseases that require therapies in which the drug must reach the brain …

Despite the increasing global incidence of brain disorders, achieving sufficient delivery
towards the central nervous system (CNS) remains a formidable challenge in terms of …

The global prevalence of neurologic disorders is rising, and yet we are still unable to deliver
most drug molecules, in therapeutic quantities, to the brain. The blood brain barrier consists …

The blood–brain barrier (BBB) prevents drugs' permeability into the brain and limits the
management of brain diseases. Intranasal delivery is a convenient route of drug …

Intranasal drug delivery is emerging as a reliable and promising pathway to deliver a wide
range of therapeutic agents including small and large molecules, peptides and proteins …